320:
diseases of vision. Conducted clinical research include the first clinical gene therapy trials (Stargardt) with a North
American center and integrated clinical of French National Reference Center on Retinal dystrophies with participation of more than 5000 patients. José-Alain Sahel coordinates large-scale European research programs on the retina, functional genomics, retinal neuroprotection, aging, and more recently on theraputicd. José-Alain Sahel is also a coordinator of a network of over 80 centres of excellence in clinical trials of retinal diseases among Europeans.
336:
vision. They also succeeded in showing that patients receiving this therapy is applicable can be identified and selected by non-invasive methods retinal imaging in high resolution, allowing to quickly benefit these patients discoveries from the laboratory. New high-resolution retinal imaging tools are also developed by José-Alain Sahel and his colleagues (optical coherence tomography, adaptive optics with Michel Paques), to refine the characterization of functional deficits and dispose of specific therapeutic efficacy and reproductibles markers.
22:
335:
at the
Friedrich Miescher from Institute for Biomedical Research in Basel, Switzerland, the research group of José-Alain Sahel and Serge Picaud was among the first transforme through optogenetics cells an artificial retina retinal photoreceptors connected to circuit and to use gene therapy to restore
315:
produce a trophic factor (called sustainability factor cones or RdCVF for Rod-derived Cone
Viability Factor) which uses the cone photoreceptors to survive. This discovery provided the biological basis for paracrine interactions between rods and cones showing that these interactions play a key role in
764:
Delyfer, Marie-Noëlle; Raffelsberger, Wolfgang; Mercier, David; Korobelnik, Jean-François; Gaudric, Alain; Charteris, David G.; Tadayoni, Ramin; Metge, Florence; Caputo, Georges; Barale, Pierre-Olivier; Ripp, Raymond; Muller, Jean-Denis; Poch, Olivier; Sahel, José-Alain; Léveillard, Thierry (2011).
339:
Currently, José-Alain Sahel is a member of the
Scientific Advisory Board of several public and private institutions : Faculty of Medicine Pierre and Marie Curie, Foundation Fighting Blindness, Steering Committee of the European Vision Institute (EVI EEIG), Chairman of the Steering Committee of
327:
people. He is one of the pioneers (with the Study Group on the retinal implant Argus II) in the
Research on visual prostheses that could potentially become a breakthrough therapy for visually disabled patients, and allow them to regain some autonomy with recognition of objects or words, orientation
303:
in Europe and combines fifteen academic and clinical teams employing more than 250 researchers. There he continued his research on developmental biology, functional genomics, physiology and therapeutics (stem cells, gene therapy, pharmacology, artificial retina), research on relevant biomarkers and
269:
and in
Lariboisière, St. Louis. In 1980 he received a Doctorate of Medicine with a Medal of the Faculty of Paris and in 1984 obtained his Specialisation in Ophthalmology. He spent his first 20 professional years in the University Hospital of Strasbourg working as ophthalmologist and after moved to
319:
Clinical research led by José-Alain Sahel is closely entangled with the experimental research: information processing, genetic, therapeutic research, including modelling, evidence of pre-clinical concepts, technological developments in imaging and surgery, forming an integrated site research on
340:
European Vision
Institute - Clinical Trials - Sites of excellence (EVI- CR), City of Paris. He serves on several editorial boards of prestigious journals such as the Journal of Clinical Investigation, Science Translational Medicine, JAMA - Ophthalmology, Progress in retinal and Eye Research .
402:
Jaillard, C; Mouret, A; Niepon, ML; Clérin, E; Yang, Y; Lee-Rivera, I; Aït-Ali, N; Millet-Puel, G; Cronin, T; Sedmak, T; Raffelsberger, W; Kinzel, B; Trembleau, A; Poch, O; Bennett, J; Wolfrum, U; Lledo, PM; Sahel, JA; Léveillard, T (May 2012).
248:
Eye Center, and the Eye and Ear
Foundation Chair of Ophthalmology. Dr. Sahel previously led the Vision Institute (French: Institut de la Vision) in Paris, a research center associated with one of the oldest eye hospitals of Europe -
482:
Busskamp, V; Duebel, J; Balya, D; Fradot, M; Viney, TJ; Siegert, S; Groner, AC; Cabuy, E; Forster, V; Seeliger, M; Biel, M; Humphries, P; Paques, M; Mohand-Said, S; Trono, D; Deisseroth, K; Sahel, JA; Picaud, S; Roska, B (2010).
270:
Quinze-Vingts
National Eye Hospital in Paris, where he became department head in 2001. At the same period he held a position of the Chief of Ophthalmology and Pathology Service at Adolphe de Rothschild Foundation.
292:
José-Alain Sahel has contributed to advancements in basic and clinical research in the field of the vision. In 1992 he founded the
Laboratory of Cellular and Molecular Physiopathology of the
277:. He was also a Visiting Professor at the Hebrew University in Jerusalem, where he collaborated with the world's leading specialists in the field, professors Daniel Albert and John Dowling.
273:
José-Alain Sahel also held the chair of the Professor of Ophthalmology at the University Pierre and Marie Curie in Paris and the Professor of Biomedical Sciences (Cumberlege Chair) at
299:
Later this laboratory became the heart of the Vision Institute that José-Alain Sahel founded in Paris in 2008. This institute is one of the largest centres of integrated research on
612:
Léveillard, T; Mohand-Saïd, S; Lorentz, O; Hicks, D; Fintz, AC; Clérin, E; Simonutti, M; Forster, V; Cavusoglu, N; Chalmel, F; Dollé, P; Poch, O; Lambrou, G; Sahel, JA (Jul 2004).
304:
disease models. The common thread of his work is understanding and prevention of central vision loss through degeneration of photoreceptor cells (retinitis pigmentosa genetic) and
682:
Frasson, M; Sahel, JA; Fabre, M; Simonutti, M; Dreyfus, H; Picaud, S (Oct 1999). "Retinitis pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse".
1031:
352:
StreetLab (created in 2011) a company dedicated to the evaluation and development of new products to improve the autonomy and quality of life of visually impaired.
917:
839:
281:
241:
358:
Pixium (founded in 2012 Pixium developing a new generation of artificial retina designed to be implanted in the eye of patients who have lost their sight)
1041:
328:
and mobility. The results obtained and published as part of an international multicentre trial on retinal prostheses have resulted in FDA authorisation.
355:
GenSight Biologics (founded in 2012 dedicated to the development of treatments for degenerative diseases of the retina based on the use of gene therapy)
50:
30:
1051:
894:
245:
316:
maintaining the viability of photoreceptor cells. RdCVF through these factor could preserve central vision in some blinding human diseases.
284:
as chair of the Department of Ophthalmology, the director of the UPMC Eye Center, and the Eye and Ear Foundation Chair of Ophthalmology.
250:
123:
104:
860:
323:
Research of José-Alain Sahel is also focused on the search for new therapeutic strategies to regain sight of visually impaired and
311:
One of the major discoveries made by José-Alain Sahel and his colleagues Thierry Léveillard and Saddek Mohand-Said is that the rod
253:
in Paris, founded in 1260. He is a pioneer in the field of artificial retina and eye regenerative therapies. He is a member of the
76:
1026:
890:"Quest to Cure Blindness: Pitt, UPMC Recruit World-Renowned Expert in Research and Therapies for Blindness and Vision Impairment"
719:
Mohand-Said, S; Deudon-Combe, A; Hicks, D; Simonutti, M; Forster, V; Fintz, AC; Léveillard, T; Dreyfus, H; Sahel, JA (Jul 1998).
305:
185:
83:
569:
Yang, Y; Mohand-Said, S; Danan, A; Simonutti, M; Fontaine, V; Clerin, E; Picaud, S; Léveillard, T; Sahel, JA (May 2009).
54:
46:
90:
35:
254:
72:
39:
274:
767:"Transcriptomic Analysis of Human Retinal Detachment Reveals Both Inflammatory Response and Photoreceptor Death"
889:
266:
238:
171:
1046:
189:
296:
in Strasbourg that specialized in translational research on the mechanisms of retinal cell degeneration.
721:"Normal retina releases a diffusible factor stimulating cone survival in the retinal degeneration mouse"
405:"Nxnl2 splicing results in dual functions in neuronal cell survival and maintenance of cell integrity"
1036:
835:
97:
944:"Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling"
528:"Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling"
447:
707:
514:
312:
61:
485:"Genetic Reactivation of Cone Photoreceptors Restores Visual Responses in Retinitis pigmentosa"
973:
798:
752:
699:
670:
635:
600:
557:
506:
470:
434:
390:
963:
955:
788:
778:
742:
732:
691:
660:
625:
590:
582:
547:
539:
496:
462:
424:
416:
382:
181:
234:
868:
386:
968:
943:
793:
766:
595:
570:
552:
527:
429:
404:
265:
José-Alain Sahel was born in Tlemcen (Algeria) in 1955. He has studied medicine in the
1020:
747:
720:
571:"Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa"
231:
207:
649:"Selective transplantation of rods delays cone loss in a retinitis pigmentosa model"
996:
711:
332:
237:
and scientist. He is currently the chair of the Department of Ophthalmology at the
518:
959:
783:
543:
811:
Partial recovery of visual function in a blind patient after optogenetic therapy
300:
665:
648:
814:
737:
501:
484:
324:
977:
802:
703:
674:
639:
604:
561:
510:
474:
438:
394:
756:
614:"Identification and characterization of rod-derived cone viability factor"
466:
420:
586:
150:
1001:
1006:
293:
161:
370:
1011:
630:
613:
349:
Fovéa Pharmaceuticals (created in 2005, acquired by Sanofi Aventis)
695:
446:
Vignal-Clermont, C; Audo, I; Sahel, JA; Paques, M (Oct 2010).
60:
from the article and its talk page, especially if potentially
15:
647:
Mohand-Said, S; Hicks, D; Dreyfus, H; Sahel, JA (Jun 2000).
861:"University College London profile for José-Alain Sahel"
918:"Le premier centre européen de la vision créé à Paris"
809:
Sahel, JA., Boulanger-Scemama, E., Pagot, C. et al.:
280:In October 2016, José-Alain Sahel was hired by the
213:
203:
177:
167:
157:
145:
138:
8:
997:The Vision Institut (Institut de la Vision)
867:. University College London. Archived from
282:University of Pittsburgh School of Medicine
815:https://doi.org/10.1038/s41591-021-01351-4
135:
53:about living persons that is unsourced or
1032:Members of the French Academy of Sciences
967:
792:
782:
746:
736:
664:
629:
594:
551:
500:
428:
124:Learn how and when to remove this message
895:University of Pittsburgh Medical Center
827:
916:Petitnicolas, Catherine (2008-03-25).
526:Léveillard, T; Sahel, JA (Apr 2010).
448:"Poppers-associated retinal toxicity"
7:
387:10.1146/annurev-neuro-062012-170304
251:Quinze-Vingts National Eye Hospital
836:José-Alain Sahel, master of vision
14:
1042:French people of Algerian descent
1052:University of Pittsburgh faculty
813:. Nat Med 27, 1223–1229 (2021).
20:
1:
960:10.1126/scitranslmed.3000866
784:10.1371/journal.pone.0028791
544:10.1126/scitranslmed.3000866
371:"Gene therapy for blindness"
369:Sahel, JA; Roska, B (2013).
31:biography of a living person
217:The Vision Institute, Paris
58:must be removed immediately
1068:
666:10.1001/archopht.118.6.807
331:With the research team of
255:French Academy of Sciences
275:University College London
221:
196:
725:Proc Natl Acad Sci U S A
306:age-related degeneration
239:University of Pittsburgh
1027:French ophthalmologists
738:10.1073/pnas.95.14.8357
502:10.1126/science.1190897
186:National Order of Merit
172:University of Strasburg
190:Wolf Prize in Medicine
45:Please help by adding
363:Selected publications
267:Strasbourg University
467:10.1056/nejmc1005118
182:The Legion of Honour
51:Contentious material
942:Sahel, JA. (2010).
1007:GenSight Biologics
842:. 2012. p. 23
587:10.1038/mt.2009.28
421:10.1093/hmg/dds050
244:, director of the
242:School of Medicine
73:"José-Alain Sahel"
375:Annu Rev Neurosci
344:Companies created
225:
224:
198:Scientific career
134:
133:
126:
108:
34:needs additional
1059:
982:
981:
971:
939:
933:
932:
930:
929:
913:
907:
906:
904:
903:
886:
880:
879:
877:
876:
857:
851:
850:
848:
847:
832:
806:
796:
786:
760:
750:
740:
715:
678:
668:
643:
633:
608:
598:
565:
555:
532:Sci. Transl. Med
522:
504:
478:
452:
442:
432:
415:(10): 2298–311.
398:
228:José-Alain Sahel
140:José-Alain Sahel
136:
129:
122:
118:
115:
109:
107:
66:
47:reliable sources
24:
23:
16:
1067:
1066:
1062:
1061:
1060:
1058:
1057:
1056:
1017:
1016:
991:
986:
985:
941:
940:
936:
927:
925:
915:
914:
910:
901:
899:
888:
887:
883:
874:
872:
859:
858:
854:
845:
843:
834:
833:
829:
824:
763:
731:(14): 8357–62.
718:
681:
653:Arch Ophthalmol
646:
611:
568:
525:
495:(5990): 413–7.
481:
450:
445:
401:
368:
365:
346:
290:
263:
235:ophthalmologist
168:Alma mater
153:
141:
130:
119:
113:
110:
67:
65:
44:
25:
21:
12:
11:
5:
1065:
1063:
1055:
1054:
1049:
1044:
1039:
1034:
1029:
1019:
1018:
1015:
1014:
1009:
1004:
999:
994:
990:
989:External links
987:
984:
983:
954:(26): 26ps16.
948:Sci Transl Med
934:
908:
881:
865:iris.ucl.ac.uk
852:
826:
825:
823:
820:
819:
818:
807:
777:(12): e28791.
761:
716:
690:(10): 1183–7.
679:
644:
631:10.1038/ng1386
609:
566:
523:
479:
461:(16): 1583–5.
443:
399:
364:
361:
360:
359:
356:
353:
350:
345:
342:
313:photoreceptors
289:
286:
262:
259:
223:
222:
219:
218:
215:
211:
210:
205:
201:
200:
194:
193:
179:
175:
174:
169:
165:
164:
159:
155:
154:
149:
147:
143:
142:
139:
132:
131:
114:September 2024
55:poorly sourced
28:
26:
19:
13:
10:
9:
6:
4:
3:
2:
1064:
1053:
1050:
1048:
1047:Living people
1045:
1043:
1040:
1038:
1035:
1033:
1030:
1028:
1025:
1024:
1022:
1013:
1012:Pixium Vision
1010:
1008:
1005:
1003:
1000:
998:
995:
993:
992:
988:
979:
975:
970:
965:
961:
957:
953:
949:
945:
938:
935:
923:
919:
912:
909:
897:
896:
891:
885:
882:
871:on 2016-03-04
870:
866:
862:
856:
853:
841:
837:
831:
828:
821:
816:
812:
808:
804:
800:
795:
790:
785:
780:
776:
772:
768:
762:
758:
754:
749:
744:
739:
734:
730:
726:
722:
717:
713:
709:
705:
701:
697:
696:10.1038/13508
693:
689:
685:
680:
676:
672:
667:
662:
659:(6): 807–11.
658:
654:
650:
645:
641:
637:
632:
627:
623:
619:
615:
610:
606:
602:
597:
592:
588:
584:
581:(5): 787–95.
580:
576:
572:
567:
563:
559:
554:
549:
545:
541:
537:
533:
529:
524:
520:
516:
512:
508:
503:
498:
494:
490:
486:
480:
476:
472:
468:
464:
460:
456:
449:
444:
440:
436:
431:
426:
422:
418:
414:
410:
409:Hum Mol Genet
406:
400:
396:
392:
388:
384:
380:
376:
372:
367:
366:
362:
357:
354:
351:
348:
347:
343:
341:
337:
334:
329:
326:
321:
317:
314:
309:
307:
302:
297:
295:
287:
285:
283:
278:
276:
271:
268:
260:
258:
256:
252:
247:
243:
240:
236:
233:
229:
220:
216:
212:
209:
208:Ophthalmology
206:
202:
199:
195:
191:
187:
183:
180:
176:
173:
170:
166:
163:
160:
156:
152:
148:
144:
137:
128:
125:
117:
106:
103:
99:
96:
92:
89:
85:
82:
78:
75: –
74:
70:
69:Find sources:
63:
59:
56:
52:
48:
42:
41:
37:
32:
27:
18:
17:
951:
947:
937:
926:. Retrieved
921:
911:
900:. Retrieved
898:. 2016-10-05
893:
884:
873:. Retrieved
869:the original
864:
855:
844:. Retrieved
830:
810:
774:
770:
728:
724:
687:
683:
656:
652:
624:(7): 755–9.
621:
617:
578:
574:
535:
531:
492:
488:
458:
455:N Engl J Med
454:
412:
408:
378:
374:
338:
333:Botond Roska
330:
322:
318:
310:
301:eye diseases
298:
291:
279:
272:
264:
227:
226:
214:Institutions
197:
120:
111:
101:
94:
87:
80:
68:
57:
40:verification
33:
1037:1955 births
924:(in French)
158:Nationality
1021:Categories
928:2018-04-11
902:2018-04-11
875:2018-02-08
846:2018-04-11
838:(Report).
822:References
538:(26): 26.
381:: 467–88.
84:newspapers
1002:StreetLab
618:Nat Genet
575:Mol. Ther
261:Biography
36:citations
978:20375363
803:22174898
771:PLOS ONE
704:10502823
675:10865319
640:15220920
605:19277021
562:20375363
511:20576849
475:20942681
439:22343139
395:23724995
288:Research
188:(2002);
184:(2008);
62:libelous
969:2896730
794:3235162
757:9653191
712:8345111
684:Nat Med
596:2835133
553:2896730
489:Science
430:3664437
308:(AMD).
151:Algeria
98:scholar
976:
966:
922:FIGARO
801:
791:
755:
745:
710:
702:
673:
638:
603:
593:
560:
550:
519:916291
517:
509:
473:
437:
427:
393:
294:Retina
232:French
204:Fields
192:(2024)
178:Awards
162:French
100:
93:
86:
79:
71:
748:20980
708:S2CID
515:S2CID
451:(PDF)
325:blind
230:is a
105:JSTOR
91:books
29:This
974:PMID
840:CNRS
799:PMID
753:PMID
700:PMID
671:PMID
636:PMID
601:PMID
558:PMID
507:PMID
471:PMID
435:PMID
391:PMID
379:2013
246:UPMC
146:Born
77:news
38:for
964:PMC
956:doi
789:PMC
779:doi
743:PMC
733:doi
692:doi
661:doi
657:118
626:doi
591:PMC
583:doi
548:PMC
540:doi
497:doi
493:329
463:doi
459:363
425:PMC
417:doi
383:doi
1023::
972:.
962:.
950:.
946:.
920:.
892:.
863:.
797:.
787:.
773:.
769:.
751:.
741:.
729:95
727:.
723:.
706:.
698:.
686:.
669:.
655:.
651:.
634:.
622:36
620:.
616:.
599:.
589:.
579:17
577:.
573:.
556:.
546:.
534:.
530:.
513:.
505:.
491:.
487:.
469:.
457:.
453:.
433:.
423:.
413:21
411:.
407:.
389:.
377:.
373:.
257:.
49:.
980:.
958::
952:2
931:.
905:.
878:.
849:.
817:.
805:.
781::
775:6
759:.
735::
714:.
694::
688:5
677:.
663::
642:.
628::
607:.
585::
564:.
542::
536:2
521:.
499::
477:.
465::
441:.
419::
397:.
385::
127:)
121:(
116:)
112:(
102:·
95:·
88:·
81:·
64:.
43:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.